The Role of ABC Transporters in Stem Cells View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2001-2010

FUNDING AMOUNT

3261625 USD

ABSTRACT

DESCRIPTION (provided by applicant): The overall goal of this research proposal is to further define the role of the Abcg2 transporter in hematopoietic stem cells (HSCs), in stem cells from other non-hematopoietic organs, and in cancer stem cells. Work in the prior funding period has shown that: 1) Abcg2 expression is required for the side population (SP) phenotype in HSCs and serves as a prospective molecular marker for isolating HSCs, 2) Abcg2-expressing SP cells exist in skeletal muscle, and as demonstrated by other labs, in many other non-hematopoietic organs, 3) a majority of human AML samples contain a small subpopulation of ABCG2-expressing cells that could represent a leukemia stem cell population, and 4) expression of Abcg2 protects HSCs from mitoxantrone, a xenobiotic drug. Experiments are now planned that will unequivocally determine whether Abcg2-expressing cells have stem cell activity in skeletal muscle and in other organ systems. By using a novel genetic approach, we will track the progeny of Abcg2-expressing cells in mice at different stages of development in order to evaluate candidate organ systems for the presence of Abcg2-expressing stem cells. A second aim is to use monoclonal antibodies to isolate hematopoietic stem cells from human and non-human primates. Using a panel of monoclonal antibodies that recognize external epitopes on ABCG2 that are present on living cells, we will isolate cells expressing ABCG2 and test them for hematopoietic stem cell function, with the ultimate goal defining a new stem cell population for use in transplantation protocols. Lastly, we will evaluate whether Abcg2 expression can identify cancer stem cells in myelogenous leukemia and in neuroblastoma. Both tumors contain a subpopulation of cells that express the side population phenotype and ABCG2, and therefore may represent a cancer stem cell population. We have and will develop novel genetic mouse models that should allow us to test this hypothesis in an unequivocal fashion. Not only could this provide a new marker for cancer stem cells, but it would have prognostic and therapeutic significance for these human cancers. Altogether, these studies should further elucidate the role of the Abcg2 transporter in normal and malignant stem cells, and should further increase our understanding of the role of ABC transporters in stem cells. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=7479086

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "3261625"
    }, 
    "description": "DESCRIPTION (provided by applicant): The overall goal of this research proposal is to further define the role of the Abcg2 transporter in hematopoietic stem cells (HSCs), in stem cells from other non-hematopoietic organs, and in cancer stem cells. Work in the prior funding period has shown that: 1) Abcg2 expression is required for the side population (SP) phenotype in HSCs and serves as a prospective molecular marker for isolating HSCs, 2) Abcg2-expressing SP cells exist in skeletal muscle, and as demonstrated by other labs, in many other non-hematopoietic organs, 3) a majority of human AML samples contain a small subpopulation of ABCG2-expressing cells that could represent a leukemia stem cell population, and 4) expression of Abcg2 protects HSCs from mitoxantrone, a xenobiotic drug. Experiments are now planned that will unequivocally determine whether Abcg2-expressing cells have stem cell activity in skeletal muscle and in other organ systems. By using a novel genetic approach, we will track the progeny of Abcg2-expressing cells in mice at different stages of development in order to evaluate candidate organ systems for the presence of Abcg2-expressing stem cells. A second aim is to use monoclonal antibodies to isolate hematopoietic stem cells from human and non-human primates. Using a panel of monoclonal antibodies that recognize external epitopes on ABCG2 that are present on living cells, we will isolate cells expressing ABCG2 and test them for hematopoietic stem cell function, with the ultimate goal defining a new stem cell population for use in transplantation protocols. Lastly, we will evaluate whether Abcg2 expression can identify cancer stem cells in myelogenous leukemia and in neuroblastoma. Both tumors contain a subpopulation of cells that express the side population phenotype and ABCG2, and therefore may represent a cancer stem cell population. We have and will develop novel genetic mouse models that should allow us to test this hypothesis in an unequivocal fashion. Not only could this provide a new marker for cancer stem cells, but it would have prognostic and therapeutic significance for these human cancers. Altogether, these studies should further elucidate the role of the Abcg2 transporter in normal and malignant stem cells, and should further increase our understanding of the role of ABC transporters in stem cells.", 
    "endDate": "2010-07-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.279885.9", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2538025", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2538025"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R01HL067366"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "non-human primates", 
      "many other non-hematopoietic organs", 
      "stem cells", 
      "majority", 
      "cancer stem cells", 
      "ABCG2", 
      "development", 
      "other organ systems", 
      "stem cell activity", 
      "experiments", 
      "Stem Cells", 
      "malignant stem cells", 
      "applicants", 
      "monoclonal antibodies", 
      "progeny", 
      "new markers", 
      "prior funding period", 
      "description", 
      "human cancers", 
      "use", 
      "ultimate goal", 
      "xenobiotic drugs", 
      "understanding", 
      "cancer stem cell population", 
      "SP cells", 
      "mice", 
      "phenotype", 
      "ABC transporters", 
      "role", 
      "novel genetic mouse model", 
      "ABC Transporters", 
      "prospective molecular marker", 
      "different stages", 
      "other non-hematopoietic organs", 
      "other labs", 
      "small subpopulation", 
      "side population", 
      "transplantation protocols", 
      "myelogenous leukemia", 
      "work", 
      "second aim", 
      "unequivocal fashion", 
      "human AML samples", 
      "novel genetic approach", 
      "hematopoietic stem cells", 
      "therapeutic significance", 
      "ABCG2 transporter", 
      "cells", 
      "subpopulations", 
      "expression", 
      "new stem cell population", 
      "presence", 
      "order", 
      "tumor", 
      "skeletal muscle", 
      "overall goal", 
      "side population phenotype", 
      "hypothesis", 
      "neuroblastoma", 
      "study", 
      "external epitope", 
      "hematopoietic stem cell function", 
      "leukemia stem cell population", 
      "mitoxantrone", 
      "research proposals", 
      "candidate organ systems", 
      "ABCG2 expression", 
      "panel"
    ], 
    "name": "The Role of ABC Transporters in Stem Cells", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.240871.8", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.240871.8", 
          "name": "ST. JUDE CHILDREN'S RESEARCH HOSPITAL", 
          "type": "Organization"
        }, 
        "familyName": "SORRENTINO", 
        "givenName": "BRIAN P", 
        "id": "sg:person.01342500537.03", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01342500537.03", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2538025"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T11:58", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_10.xml.gz", 
    "startDate": "2001-05-15T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=7479086"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2538025'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2538025'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2538025'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2538025'


 

This table displays all metadata directly associated to this object as RDF triples.

112 TRIPLES      19 PREDICATES      90 URIs      82 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2538025 schema:about anzsrc-for:2211
2 schema:amount N1875942efe6b4a16b58a5c5834e84be1
3 schema:description DESCRIPTION (provided by applicant): The overall goal of this research proposal is to further define the role of the Abcg2 transporter in hematopoietic stem cells (HSCs), in stem cells from other non-hematopoietic organs, and in cancer stem cells. Work in the prior funding period has shown that: 1) Abcg2 expression is required for the side population (SP) phenotype in HSCs and serves as a prospective molecular marker for isolating HSCs, 2) Abcg2-expressing SP cells exist in skeletal muscle, and as demonstrated by other labs, in many other non-hematopoietic organs, 3) a majority of human AML samples contain a small subpopulation of ABCG2-expressing cells that could represent a leukemia stem cell population, and 4) expression of Abcg2 protects HSCs from mitoxantrone, a xenobiotic drug. Experiments are now planned that will unequivocally determine whether Abcg2-expressing cells have stem cell activity in skeletal muscle and in other organ systems. By using a novel genetic approach, we will track the progeny of Abcg2-expressing cells in mice at different stages of development in order to evaluate candidate organ systems for the presence of Abcg2-expressing stem cells. A second aim is to use monoclonal antibodies to isolate hematopoietic stem cells from human and non-human primates. Using a panel of monoclonal antibodies that recognize external epitopes on ABCG2 that are present on living cells, we will isolate cells expressing ABCG2 and test them for hematopoietic stem cell function, with the ultimate goal defining a new stem cell population for use in transplantation protocols. Lastly, we will evaluate whether Abcg2 expression can identify cancer stem cells in myelogenous leukemia and in neuroblastoma. Both tumors contain a subpopulation of cells that express the side population phenotype and ABCG2, and therefore may represent a cancer stem cell population. We have and will develop novel genetic mouse models that should allow us to test this hypothesis in an unequivocal fashion. Not only could this provide a new marker for cancer stem cells, but it would have prognostic and therapeutic significance for these human cancers. Altogether, these studies should further elucidate the role of the Abcg2 transporter in normal and malignant stem cells, and should further increase our understanding of the role of ABC transporters in stem cells.
4 schema:endDate 2010-07-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.279885.9
6 schema:identifier N748ee449d5684421b32574ae5a1880c1
7 N7eca3d138fbb4ce5b84648aee2f1bb13
8 schema:inLanguage en
9 schema:keywords ABC Transporters
10 ABC transporters
11 ABCG2
12 ABCG2 expression
13 ABCG2 transporter
14 SP cells
15 Stem Cells
16 applicants
17 cancer stem cell population
18 cancer stem cells
19 candidate organ systems
20 cells
21 description
22 development
23 different stages
24 experiments
25 expression
26 external epitope
27 hematopoietic stem cell function
28 hematopoietic stem cells
29 human AML samples
30 human cancers
31 hypothesis
32 leukemia stem cell population
33 majority
34 malignant stem cells
35 many other non-hematopoietic organs
36 mice
37 mitoxantrone
38 monoclonal antibodies
39 myelogenous leukemia
40 neuroblastoma
41 new markers
42 new stem cell population
43 non-human primates
44 novel genetic approach
45 novel genetic mouse model
46 order
47 other labs
48 other non-hematopoietic organs
49 other organ systems
50 overall goal
51 panel
52 phenotype
53 presence
54 prior funding period
55 progeny
56 prospective molecular marker
57 research proposals
58 role
59 second aim
60 side population
61 side population phenotype
62 skeletal muscle
63 small subpopulation
64 stem cell activity
65 stem cells
66 study
67 subpopulations
68 therapeutic significance
69 transplantation protocols
70 tumor
71 ultimate goal
72 understanding
73 unequivocal fashion
74 use
75 work
76 xenobiotic drugs
77 schema:name The Role of ABC Transporters in Stem Cells
78 schema:recipient Nbc548092b13243acb04ee000a73d88de
79 sg:person.01342500537.03
80 https://www.grid.ac/institutes/grid.240871.8
81 schema:sameAs https://app.dimensions.ai/details/grant/grant.2538025
82 schema:sdDatePublished 2019-03-07T11:58
83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
84 schema:sdPublisher Nf6aff988faff4f8d9bb34afb68b054cf
85 schema:startDate 2001-05-15T00:00:00Z
86 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=7479086
87 sgo:license sg:explorer/license/
88 sgo:sdDataset grants
89 rdf:type schema:MonetaryGrant
90 N1875942efe6b4a16b58a5c5834e84be1 schema:currency USD
91 schema:value 3261625
92 rdf:type schema:MonetaryAmount
93 N748ee449d5684421b32574ae5a1880c1 schema:name nih_id
94 schema:value R01HL067366
95 rdf:type schema:PropertyValue
96 N7eca3d138fbb4ce5b84648aee2f1bb13 schema:name dimensions_id
97 schema:value 2538025
98 rdf:type schema:PropertyValue
99 Nbc548092b13243acb04ee000a73d88de schema:member sg:person.01342500537.03
100 schema:roleName PI
101 rdf:type schema:Role
102 Nf6aff988faff4f8d9bb34afb68b054cf schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
105 rdf:type schema:DefinedTerm
106 sg:person.01342500537.03 schema:affiliation https://www.grid.ac/institutes/grid.240871.8
107 schema:familyName SORRENTINO
108 schema:givenName BRIAN P
109 rdf:type schema:Person
110 https://www.grid.ac/institutes/grid.240871.8 schema:name ST. JUDE CHILDREN'S RESEARCH HOSPITAL
111 rdf:type schema:Organization
112 https://www.grid.ac/institutes/grid.279885.9 schema:Organization
 




Preview window. Press ESC to close (or click here)


...